# HELIX, a Double-masked Study of SYL1001 in Patients With Moderate to Severe Dry Eye Disease (DED)

> **NCT03108664** · PHASE3 · COMPLETED · sponsor: **Sylentis, S.A.** · enrollment: 330 (actual)

## Conditions studied

- Dry Eye Disease

## Interventions

- **DRUG:** SYL1001 ophthalmic solution
- **DRUG:** Vehicle opthalmic solution

## Key facts

- **NCT ID:** NCT03108664
- **Lead sponsor:** Sylentis, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-18
- **Primary completion:** 2018-10-16
- **Final completion:** 2018-11-16
- **Target enrollment:** 330 (ACTUAL)
- **Last updated:** 2019-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03108664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03108664, "HELIX, a Double-masked Study of SYL1001 in Patients With Moderate to Severe Dry Eye Disease (DED)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03108664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*